A Study of BMS-986504 in Participants With Pre-treated Advanced or Metastatic Non-small Cell Lung Cancer (NSCLC) With Homozygous MTAP Deletion (MountainTAP-9)
Phase 2
130
about 6.3 years
18+
12 sites in AK, ID, MA +7
About this study
This trial is testing a treatment called BMS-986504 for people with advanced lung cancer that has not responded to other treatments. The goal is to see if BMS-986504 can help improve the lives of these patients.
Based on ClinicalTrials.gov records.
What participants do
- 1.Take BMS-986504
Participation effort
Estimated from trial records. Details can vary by site.
Logistics difficulty varies by site location and availability.
Trial highlights
Treatment details
Auto-extracted from trial records to preview treatments and outcomes.
Primary: Number of participants who achieve Objective Response (OR) utilizing the Response Evaluation Criteria in Solid Tumors (RECIST) v1.1
Secondary: Change from baseline in cancer-related symptoms and health-related quality of life as assessed by the EORTC-QLQ-F17 quality-of-life (QoL) functional scale score, Change from baseline in cancer-related symptoms and health-related quality of life as assessed by the European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire Core Function Global Health Status functional scale score, Change from baseline in cancer-related symptoms and health-related quality of life as assessed by the Non-small Cell Lung Cancer Symptom Assessment Questionnaire (NSCLC-SAQ) total score and symptom score, Duration of response (DOR) as assessed by RECIST v1.1, Number of deaths, Number of participants who achieve Objective Response (OR) as assessed by RECIST v1.1, Number of participants with AEs leading to dose interruption, reduction, or discontinuation, Number of participants with Serious AEs (SAEs)
Oncology